SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ARENA PHARMACEUTICALS INC
(NQNM:ARNA Last Sale: 51.28 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ARNA : $51.28)
$2,579,215 million Market Cap at Market Close, July 1, 2022
Employs 360.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
6166 Nancy Ridge Dr Research Report Earnings Snapshot - Last 11/03/18
San Diego, CA 92121 Fact Sheet
Phone: (858) 453-7200 Financial Statements
Fax: (858) 453-7210 Peer Comparison
Annual Reports

Jack Lief, Co-Founder/Chmn./Pres./CEO, Dominic P. Behan, Co-Founder, Robert E. Hoffman, CFO
June 27, 2012, BELVIQ approved by the FDA. Unfavorable FDA rebuke on diet drug, lorcaserin, raising safety questions about effects on the heart, September 14, 2010. Arena studied the drug in more than 7,000 obese and overweight patients. After one year, the average weight loss among lorcaserin patients was 5.8 pounds, compared with 2.5 pounds among patients on the placebo. Markets a proprietary screening technology which enables identification of drug candidates. IPO at $18 July 27, 2000. Raised $108 million, selling 6 million shares, 29% of the outstanding. Lead Manager: ING Barings. Secondary sold 7.5 million shares at $6 February 1, 2005. Secondary sold 9.8 million shares at $16.90, January 26, 2006.
Historical Charts    Technical Analysis
No Historical Data available for ARNA

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ARNA $51.28 $51.28 0 .0 $46.9 $51.42 576,871 $46.9 $51.42 50,296,714
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex